Our research group examines transcriptomics, gene polymorphisms, metabolomics, and proteomics to identify biomarkers that predict disease progression and the response to antiviral therapy of individual patients chronically infected with HBV, HCV, HEV and HIV.

Transcriptomes of peripheral blood, liver cells and purified immune cells (B cell, T cell, NK cell, monocytes) obtained from patients infected with HBV, HCV, or HIV are profiled by microarray, bulk RNA-seq and single cell RNA-Seq. The transcriptomes are evaluated in detail using analyses for individual genes and gene sets/modules to understand molecular factors underlying the disease progression, differential responses to therapeutic intervention, and predictive values of gene expression.

SNP analysis and GWAS to discover genetic variants and genomic biomarkers associated with susceptibility of consecutive disease progression and to therapeutic response.